EXCEL Biodegradable Polymer DES Multi-center Prospective Registry Study

Between June and November 2006,2077 patients, exclusively treated with Excel stents at 59 centers from 4 countries, were enrolled in this prospective ,multicenter registry.

CREATE study has been published on a number of globally authoritative academic conferences and magazines.

CREATE Study Six-month Follow-up Results

① Abstract of CREATE study report selected as the plenary lecture of TCT 2007 (Ballroom C);

② Abstract of CREATE study paper published on Am J Cardiol 2007; 100(8): 160.TCT-410.

CREATE Study One-year Follow-up Results

① CREATE study one-year result selected as presenting speech at 2008 CIT Beijing, China;

② CREATE study one-year result selected as the plenary lecture by Late Breaking Clinical Trial (LBCT) of 2008 ACC-i2. On behalf of CREATE Research Group, Professor Yaling Han delivered the report of CREATE Research One-year Results.

CREATE Study Eighteen-month Follow-up Results

① 18 month follow-up results have been published at the TCT (Transcatheter Cardiovascular Therapeutics) in October 2008;

② On March 28, 2009, CREATE study eighteen-month results were exchanged on the poster at Orlando ACC-i2, and published on JACC, 2009, 53 (10, Supplement): A9;

③ CREATE Study Eighteen-month Follow-up Results, Safety and Efficacy of Biodegradable Polymer-Coated Sirolimus-Eluting Stents in "Real-World" Practice Eighteen-Month Clinical and Nine-Month Angiographic Outcomes was published on J Am Coll Cardiol Cardiovascular Intervention. 2009; 2: 303-309 (2011 latest influential factor 5.862).

CREATE Study Three-year Follow-up Results

① Presented at CIT (China National Convention Center) in March 2010;

② Sub-group-diabetes mellitus study selected for the poster exchange by ACC (American College of Cardiology) held in March 2010, and its abstract published on JACC 2010; 55 (10A Supplement1): A158;

③ Presented at China Scholars Clinical Trial (China National Convention Center) of WCC Beijing organized by China Cardiovascular Disease Association in June 2010;

④ Presented at 15th WORLD CONGRESS ON HEART DISEASE held in Vancouver, Canada in July 2010;

⑤ Selected for exchange on poster by TCT in 2010, and its abstract was published on JACC 2010; 56 (13 Supplement); B52.

CREATE Study Four-year Follow-up Results

① Published for the first time at 2011 CIT;

② Published in the wall newspaper area at ESC2011.

CREATE Study Four-year Follow-up Results Showcases:  

EXCEL Stent shows a good safety in the "real world"

EXCEL shows extremely low MACE, TLR and stent thrombosis

MACE is only 5%; TLR is only2.8%; ARC definite & ARC probable is only 1.2%

Six-month DAPT(dual anti-platelet treatment) after implanting EXCEL Stent seems safe

Without obvious late catch-up phenomenon compared to other clinical trials

EXCEL Stent demonstrate sound clinical effect

CREATE Study Five-Year Follow-up Results

Follow-up results were firstly presented at CIT 2012;

Follow-up results were presented at North China Cardiovascular Forum 2012

Follow-up results were presented at TCT RUSSIA 2012

Follow-up results were presented at Xi'an International Cardiovascular Forum 2012

Subgroup analysis results were presented at CHC 2012.

According to CREATE 5-Year Follow-up Results

Current data suggests a high degree of safety of the Excel biodegradable polymer based SES, even though being used in  "real world" settings

Up to 5-year clinical outcomes indicate a sustained efficacy of Excel stent and late catch-up phenomenon is not significant

6-month dual antiplatelet treatment seems safe after Excel stent implantation